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Summary Expression of the bc1-2 proto-oncogene was studied immunohistochemically in 251 invasive ductal
breast carcinomas (median follow-up time 91 months, range 24-186 months) and the-results were correlated
with clinicopathological data and prognostic variables. Sixty-three (25%) tumours were scored bcl-2 negative
and 188 (75%) tumours were bcl-2 positive. No relationship could be observed between bcl-2 status and
tumour grade, pTNM staging or menopausal status. A strong positive relationship was demonstrated between
bcl-2 immunoreactivity and oestrogen receptor status (P<0.001) and progesterone receptor status (P<0.001).
No prognostic value was demonstrated for bcl-2 expression on disease-free survival and overall survival in
axillary node-negative breast cancer patients. However, in axillary node-positive breast cancer patients
multivariate analysis demonstrated absence of bcl-2 expression to be independently related to shortened
disease-free survival (P=0.003) and shortened overall survival (P<0.001). Our results suggest a potential
important role for bcl-2 expression as a modulator of response to adjuvant therapy in breast cancer.
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Cloning of the t(14;18) chromosomal breakpoint in follicular
lymphoma led to the discovery of the bc1-2 proto-oncogene
(Tsujimoto et al., 1984; Cleary et al., 1986; Tsujimoto and
Croce, 1986). Gene transfer experiments have demonstrated a
role for bcl-2 in preventing apoptosis in growth factor-
deprived haemopoietic cell lines (Vaux et al., 1988; Nuiiez et
al., 1990) and in neurotrophic factor-deprived neurons (Gar-
cia et al., 1992; Allsopp et al., 1993). In transgenic mice bct-2
has been shown to prolong cell survival (McDonnell et al.,
1989; Strasser et al., 1990). Antisense-mediated inhibition of
bcl-2 gene expression reduces leukaemic cell growth and sur-
vival in an in vitro setting (Reed et al., 1990). Hockenberry et
al. (1990) concluded bcl-2 to be unique among proto-
oncogenes by its ability to block programmed cell death
without promoting cell proliferation, which led to its
categorisation as a member of a new category of oncogenes:
regulators of cell death (Korsmeyer, 1992).
The 25 kDA bcl-2 protein contains a hydrophobic COOH-
terminal region allowing post-translational insertion into int-
racellular membranes and orientation towards the cytosol
(Chen-Levy and Cleary, 1990). Studies on the subcellular
location of the bcl-2 protein have demonstrated its residence
in the nuclear envelope, parts of the endoplasmic reticulum,
the outer mitochondrial membrane and to a lesser extent in
the plasma membrane (Krajewski et al., 1993; Akao et al.,
1994; de Jong et al., 1994). Although its exact biochemical
mechanism of action remains largely unexplained, an impor-
tant physiological role for bcl-2 in cell development and
differentiation, in tissue homeostasis and in morphogenesis
was shown in immunohistochemical studies on fetal and
adult human tissues of different origin (Hockenberry et al.,
1991; LeBrun et al., 1993; Lu et al., 1993).
Immunohistochemical studies on bcl-2 expression in
human breast cancer have demonstrated a strong association
with oestrogen receptor (ER) status, illustrating the pos-
sibility that bcl-2 is an ER regulated gene (Bhargava et al.,
1994; Chan et al., 1993; Doglioni et al., 1994; Gee et al.,
1994; Leek et al., 1994; Nathan et al., 1994; Silvestrini et al.,
1994). The presence of bcl-2 protein immunostaining has
been shown to be associated with a low apoptotic index in
malignant mammary epithelium (Chan et al., 1993). Leek et
al. (1994) did not demonstrate a correlation between bcl-2
status and tumour size, nodal status, tumour grade and
histological type in 111 breast carcinomas. By contrast other
authors correlated bcl-2 immunoreactivity with larger tumour
size, with the lobular type and with better differentiated
neoplasms (Bhargava et al., 1994; Doglioni et al., 1994;
Joensuu et al., 1994; Silvestrini et al., 1994). An inverse
correlation was noticed between bcl-2 protein expression and
proliferative activity as measured by Ki 67 immunostaining
and [3H]thymidine labelling index (Doglioni et al., 1994;
Silvestrini et al., 1994). Furthermore, loss of bcl-2 expression
has been associated with presence of a range of molecular
markers of poor prognosis in breast cancer, including epider-
mal growth factor receptor (EGFR), c-erb-B2 and p53 (Dog-
lioni et al., 1994; Gee et al., 1994; Joensuu et al., 1994; Leek
et al., 1994; Nathan et al., 1994; Silvestrini et al., 1994). In a
recently published study on bcl-2 expression in axillary node-
negative breast cancer, no prognostic role for bct-2 on 6 year
relapse-free and overall survival was retained following mul-
tivariate analysis (Silvestrini et al., 1994). In a series of 174
breast cancers with long-term follow-up, which were primar-
ily treated by surgery with or without locoregional radio-
therapy, no prognostic role for bcl-2 expression was observed
following multivariate analysis (Joensuu et al., 1994).
The aim of the present study was to determine immunohis-
tochemically the expression of the bcl-2 proto-oncogene in a
series of invasive ductal breast cancers and to evaluate the
prognostic value of bcl-2 expression in axillary node-negative
and axillary node-positive breast cancer.
Materials and methods
Patients andfollow-up
The study group consisted of 251 women who underwent
surgery for primary invasive ductal breast carcinoma between
March 1979 and June 1992 at the Antwerp University Hos-
pital. The median age of the patients at the time of diagnosis
was 56 years (range 27-89 years). All patients had a
preoperative chest radiograph, bone scintigraphy, ultrasound
scan of the liver and blood test (full blood count, liver
function tests, carcinoembryonic antigen). If there was no
evidence of metastatic disease they were surgically treated by
modified radical mastectomy or wide local excision of the
primary tumour with axillary lymphadenectomy. All patients
who had breast conserving surgery received adjuvant
radiotherapy. Patients were pathologically staged according
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1995to the UICC (1992) TNM Atlas criteria. All tumours were
histologically classified as invasive ductal breast carcinomas
and graded according to the methodology of Bloom and
Richardson (1957). Data on tumour grade, tumour size,
nodal status, presence or absence of metastatic disease and
menopausal status are given in Table I. Menopausal status
was assessed using serum gonadotrophin and oestradiol
measurements in perimenopausal patients. Axillary node-
negative patients were followed conservatively and received
no adjuvant treatment. Axillary node-positive premenopausal
patients had six cycles of CMF (cyclophosphamide,
methotrexate and 5-fluorouracil) polychemotherapy. Axillary
node-positive post-menopausal patients received adjuvant
endocrine treatment (tamoxifen, 20 mg day-' orally). All
patients underwent a follow-up physical examination every 6
months and had further investigations if they developed
symptoms or signs suggestive of recurrent or metastatic
disease. The median follow-up time in our study group was
91 months (range 24-186 months). Ethical committee app-
roval was sought and received for this clinical study.
Immunohistochemistry
Formalin-fixed, paraffin-embedded representative primary
tumour samples were available for all patients. Five-micron-
thick sections were cut and mounted onto 3-
aminopropyltriethoxysilane-coated glass slides. They were
dewaxed in xylene followed by rehydration in decreasing
ethanol series, water and phosphate-buffered saline (PBS) pH
7.4. Endogenous peroxidase activity was quenched in 0.3%
hydrogen peroxide in 100% methanol, followed by rehydra-
tion through graded ethanol and distilled water. Subse-
quently an antigen retrieval procedure for formalin-fixed
paraffin sections was performed by immersion of the slides in
10 mM citrate buffer (10 mM citrate monohydrate in distilled
water, pH 6.0) and exposure to microwave irradiation twice
for 5 min with a cooling period of 3 min in between the
Table I Bcl-2 cytoplasmic immunoreactivity in relation to tumour
grade, pTNM staging, ER status, PgR status and menopausal status
Bcl-2 cytoplasmic immunoreactivity Significance
Bcl-2 negative Bcl-2positive P-valuea
All tumours 63 (25%) 188 (75%)
Tumour grade:
Grade I 15 (24%) 56 (30%)
Grade II 32 (51%) 85 (45%) NS
Grade III 16 (25%) 47 (25%)
Tumour sizeb
pTl 28 (44%) 91 (48%)
pT2 24 (38%) 67 (36%) NS
pT3 6 (10%) 10 (5%)
pT4 5 (8%) 20 (11%)
Nodal statusb
pNO 33 (52%) 91 (48%)
pNl 20 (32%) 64 (34%) NS
pN2 9 (14%) 14 (8%)
pNX 1 (2%) 19 (10%)
Metastasesb
MO 62 (98%) 169 (90%) NS*
Ml 1 (2%) 19 (10%)
ER statusc
Positive 22 (35%) 135 (72%) <0.001*
Negative 41 (65%) 53 (28%)
PgR statusd
Positive 26 (41%) 125 (67%) <0.001*
Negative 37 (59%) 63 (33%)
Menopause 22 (35%) 63 (33%) NS*
Post 41 (65%) 125 (67%)
aChi-squared test. bPathological tumour staging according to UICC
criteria. cOestrogen receptor status. dProgesterone receptor status.
*Yates' correction for small numbers. NS, not significant.
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sessions (Cattoretti et al., 1992). After cooling to room
temperature slides were removed to PBS and preincubated
with 10% normal rabbit serum (Dako, Denmark) to reduce
non-specific binding. The sections were incubated overnight
at 4°C with monoclonal mouse anti-human bcl-2 oncoprotein
(clone 124, isotype IgGI; Dako) diluted 1:40 in PBS supp-
lemented with 1% bovine serum albumin. This monoclonal
mouse antibody is directed towards a synthetic peptide com-
prising amino acids 41-54 of the human bcl-2 protein
(Cleary et al., 1986; Tusjimoto and Croce, 1986; Pezzella et
al., 1990). Its efficacy has been proven on frozen sections and
on paraffin sections (Pezzella et al., 1990, 1992, 1993; LeBrun
et al., 1992; Leek et al., 1994; Silvestrini et al., 1994). The
sections were then overlaid with biotinylated rabbit anti-
mouse polyclonal antibody (Dako) diluted 1:300. Binding
was detected by applying the avidin-biotin-peroxidase com-
plex (Dako). DAB (3-3'-diaminobenzidine tetrahydroch-
loride) was used as chromogen and Mayer's haematoxylin
was used as counterstain. Negative controls were performed
by omitting the primary antibody and by substituting the
anti-bcl-2 antibody for an unrelated monoclonal antibody of
the same isotype IgGI in the same concentration but directed
against an unrelated antigen (monoclonal mouse anti-human
CD68 antibody, isotype IgGI; Dako). Sections of a follicular
lymphoma were used as positive controls (Cleary et al., 1986;
Tusjimoto and Croce, 1986).
Bcl-2 cytoplasmic immunoreactivity was quantified by
counting at least 1000 tumour cells in different random fields,
using a high-power (400 x ) objective. Results were expressed
as percentage of tumour cells staining positively for bcl-2.
For further statistical analysis two groups of tumours were
defined: tumours containaing 10% or less (bcl-2 negative)
and tumours containing more than 10% positively staining
tumour cells (bcl-2 positive). This cut-off value was chosen
taking into account statistical guidelines for prognostic factor
studies in oncology (Simon and Altman, 1994).
Quantification ofsteroid hormone receptors
Oestrogen receptor (ER) and progesterone receptor (PgR)
were determined using an enzymatic assay (Abbott Enzyme
Immunoassay-Oestrogen Receptor, Abbott Enzyme
Immunoassay-Progesterone Receptor). Results were exp-
ressed quantitatively as amount of receptor protein per gram
of tissue (fmol g-1). Values greater than 20 fmol g-' tissue
protein were considered positive.
Statistical analysis
A chi-squared test was performed to evaluate the relationship
between bcl-2 immunoreactivity and tumour grade, tumour
size, nodal status, presence or absence of metastases, oest-
rogen receptor (ER) status, progesterone receptor (PR) status
and menopausal status.
Overall survival curves and disease-free survival curves,
starting from the date of surgery, were plotted using the
Kaplan and Meier (1958) method and their statistical
significance was calculated by use of the log-rank test.
Locoregional disease relapse and/or distant metastases were
considered end points for disease-free survival. Cox's (1972)
proportional hazard regression analysis was used for mul-
tivariate analysis and for calculation of the hazard ratios and
their confidence intervals.
For all statistical analyses a P-value <0.05 was considered
statistically significant.
Results
Tissue distribution ofbcl-2 immunoreactivity
Sixty-three (25%) tumours were scored as bcl-2 negative and
188 (75%) tumours were scored as bcl-2 positive. In bcl-2-
positive cases no relationship was observed between location
of bcl-2 immunoreactivity and definite neoplastic areasBcl-2expression inbreast cancer
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(tumour centre vs infiltrative margins). In all tumour sections
stromal fibroblasts were bcl-2 negative and lymphocytes were
bcl-2 positive. Cytoplasmic immunoreactivity for bcl-2 pro-
tein was always observed in normal mammary glandular
tissue in those sections containing normal breast tissue adja-
cent to the tumour.
Association with clinicopathological variables
Correlations between bcl-2 immunoreactivity and
clinicopathological variables are shown in Table I. No rela-
tionship was demonstrated between bcl-2 immunoreactivity
and tumour grade, tumour size, nodal status, presence or
absence of metastases or menopausal status. A significant
positive relationship was found between bcl-2 immunoreac-
tivity and oestrogen receptor status (P<0.001) or pro-
gesterone receptor status (P<O.001).
Prognostic relevance
In the group of patients initially staged as MO (n = 231)
(median follow-up time 91 months, range 24-186 months)
univariate analysis demonstrated a significantly shorter
disease-free survival (log-rank test, P<O.001) and a
significantly shorter overall survival (log-rank test, P<0.001)
in bcl-2-negative tumours vs bcl-2-positive tumours (Figure
1). The joint effect of bcl-2 status, tumour grade, tumour
size, nodal status and ER status on disease-free survival and
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overall survival as evaluated by Cox regression analysis is
given in Table II. In multivariate analysis bcl-2 status,
tumour grade, tumour size and nodal status were indicators
for disease-free survival and, with the exception of tumour
size, overall survival. Cox regression analysis following
adjustment for tumour grade, tumour size, nodal status and
ER status demonstrated a significantly shorter disease-free
survival (adjusted hazard ratio = 2.08, 95% CI 1.25-3.45,
P = 0.005) and a significantly shorter overall survival
(adjusted hazard ratio = 2.49, 95% CI 1.43-4.33, P = 0.001)
in bcl-2-negative tumours vs bcl-2-positive tumours.
In the group of axillary node-negative patients (n = 124)
(median follow-up time 84 months, range 24-161 months)
univariate analysis revealed no statistical difference in
disease-free survival (log-rank test, P = 0.077) or in overall
survival (log-rank test, P = 0.139) between bcl-2-negative and
bcl-2-positive tumours (Figure 2). The joint effect of bcl-2
status, tumour grade, tumour size and ER status on disease-
free survival and overall survival as evaluated by Cox regres-
sion analysis is given in Table III. Multivariate analysis by
Cox regression analysis following adjustment for tumour
grade, tumour size and ER status did not show a statistical
difference in disease-free survival (adjusted hazard
ratio = 1.52, 95% CI 0.-64-3.58, P = 0.351) or in overall
survival (adjusted hazard ratio = 1.63, 95% CI 0.63-4.22,
P = 0.326) between bcl-2-negative tumours and bcl-2-positive
tumours.
In the group of axillary node-positive patients (n = 107)
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Figure 1 Kaplan-Meier life table analysis for disease-free sur-
vival (log-rank test, P<0.001) and for overall survival (log-rank
test, P<0.001) in patients initially staged as MO (n = 231).
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Figure 2 Kaplan-Meier life table analysis for disease-free sur-
vival (log-rank test, P = 0.077) and for overall survival (log-rank
test, P = 0.139) in axillary node-negative patients (n = 124).
Table II Multivariate analysis of disease-free survival and overall survival in 231 patients initially staged as MO (Cox regression
analysis)
Disease-free survival Overall survival
HR' (95% CI) LRSb P HR' (95% CI) LRSb p
Bcl-2 expression (negativec vs positive) 2.08 (1.25-3.45) 7.78 0.005 2.49 (1.43-4.33) 10.16 0.001
Tumour grade (I, II, II)d 1.45 (1.04-2.01) 4.92 0.026 2.15 (1.48-3.12) 17.58 <0.001
Tumour size (pTI, pT2, pT3, pT4)d 1.32 (1.01-1.73) 4.02 0.045 1.21 (0.90-1.62) 1.61 0.205
Nodal status (pNO, pN1, pN2)d 1.69 (1.20-2.37) 8.97 0.003 1.66 (1.13-2.44) 6.71 0.01
ER status (positivec vs negative) 0.66 (0.40-1.10) 2.55 0.111 0.78 (0.45-1.35) 0.79 0.374
aAdjusted hazards ratio of relapsing or dying (95% confidence intervals). bLikelihood ratio statistic on one degree offreedom.
cReference category. dMean hazard ratio between two adjacent categories.
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(median follow-up time: 101 months, range 32-186 months)
univariate analysis demonstrated a significantly shorter
disease-free survival (log-rank test, P<0.001) and a
significantly shorter overall survival (log-rank test, P<0.001)
in bcl-2-negative tumours than in bcl-2-positive tumours
(Figure 3). The joint effect of bcl-2 status, tumour grade,
tumour size and ER status on disease-free survival and
overall survival as evaluated by Cox regression analysis is
given in Table IV. In multivariate analysis bcl-2 status,
tumour grade and tumour size were independent indicators
of disease-free survival and, with the exception of tumour
size, overall survival. Multivariate analysis by Cox regression
analysis following adjustment for tumour grade, tumour size
and ER status demonstrated a significantly shorter disease-
free survival (adjusted hazard ratio = 2.82, 95% CI
1.41-5.64, P = 0.003) and a significantly shorter overall sur-
vival (adjusted hazard ratio = 3.76, 95% CI 1.78-7.92,
P<0.001) in bcl-2-negative tumours than in bcl-2-positive
tumours.
It needs to be emphasised that our survival curves for
disease-free survival and overall survival in the different
patient groups have been plotted up to 180 months, although
the median follow-up period in our study group was 91
months. Owing to the limited number of patients at risk at
the end of the curves, disease-free survival rates and overall
survival rates beyond 130 months follow-up time should be
interpreted with caution (Figures 1-3).
Discussion
The bcl-2 proto-oncogene has been demonstrated to be an
inhibitor of programmed cell death without promoting cell
proliferation (Hockenberry et al., 1990). We studied the exp-
ression of the bcl-2 gene in a series of 251 invasive ductal
breast carcinomas and correlated its expression with
clinicopathological data and prognosis. Cytoplasmic
immunoreactivity for bcl-2 in more than 10% of tumour cells
was present in 188 (75%) tumours, which were considered
bcl-2 positive. Sixty-three (25%) tumours containing 10% or
fewer positively staining tumour cells were considered bcl-2
negative. We could not demonstrate a relationship between
bcl-2 immunoreactivity and tumour grade, tumour size, nodal
status, presence or absence of metastases and menopausal
status.
In the present study we observed a strong positive relation-
ship between bcl-2 immunoreactivity and oestrogen and pro-
gesterone receptor status. This is in agreement with
previously published data (Chan et al., 1993; Bhargava et al.,
1994; Doglioni et al., 1994; Gee et al., 1994; Leek et al., 1994;
Nathan et al., 1994; Silvestrini et al., 1994). These observa-
tions support the hypothesis that bcl-2 expression in breast
carcinoma may be an oestrogen receptor-regulated
phenomenon.
Silvestrini et al. (1994) studied the prognostic value of the
bcl-2 oncoprotein on 6 year relapse-free and overall survival
in 283 axillary node-negative breast cancer patients.
Univariate analysis demonstrated low bcl-2 immunoreactivity
to be associated with shortened relapse-free and overall sur-
vival. Multivariate analysis including bcl-2 status, tumour
size [3H]thymidine labelling index and ER status demon-
strated an independent prognostic role for bcl-2 expression.
However, no prognostic role for bcl-2 expression on 6 year
relapse-free survival and overall survival was retained when
p53 expression was included in the multivariate analysis
(Silvestrini et al., 1994). In a series of 174 women with breast
cancer treated with radical surgery with or without
locoregional radiotherapy and with very long-term follow-up
(median 31 years), a significant association was demonstrated
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Figure 3 Kaplan-Meier life table analysis for disease-free sur-
vival (log-rank test, P<0.001) and for overall survival (log-rank
test, P< 0.001) in axillary node-positive patients (n = 107).
Table III Multivariate analysis ofdisease-free survival and overall survival in 124 axillary node-negative patients (Cox regression
analysis)
Disease-free survival Overall survival
HR8 (95% CI) LRSb p HRZ (95% CI) LRSb p
Bcl-2 expression (negativec vs positive) 1.52 (0.64-3.58) 0.87 0.351 1.63 (0.63-4.22) 0.96 0.326
Tumour grade (I, II, II)d 1.06 (0.62-1.82) 0.05 0.818 1.84 (0.97-3.53) 3.55 0.059
Tumour size (pTl, pT2, pT3, pT4)d 1.33 (0.80-2.22) 1.09 0.296 1.47 (0.85-2.53) 1.69 0.194
ER status (positivec vs negative) 0.37 (0.16-0.88) 5.16 0.023 0.53 (0.21-1.35) 1.80 0.180
'Adjusted hazards ratio of relapsing or dying (95% confidence intervals). hLikelihood ratio statistic on one degree of freedom.
cReference category. dMean hazard ratio between two adjacent categories.
Table IV Multivariate analysis ofdisease-free survival and overall survival in 107 axillary node-positive patients (Cox regression
analysis)
Disease-free survival Overall survival
HR8 (95% CI) LRS' P HR8 (95% CI) LRSb p
Bcl-2 expression (negativec vs positive) 2.82 (1.41-5.64) 8.59 0.003 3.76 (1.78-7.92) 12.34 <0.001
Tumour grade (I, II, II)d 1.88 (1.22-2.93) 8.40 0.004 2.53 (1.55-4.12) 15.18 <0.001
Tumour size (pTl, pT2, pT3, pT4)d 1.42 (1.05-1.92) 4.97 0.026 1.19 (0.87-1.63) 1.21 0.271
ER status (positivec vs negative) 1.02 (0.51-2.04) 0.002 0.962 0.98 (0.46-2.08) 0.003 0.960
8Adjusted hazards ratio of relapsing or dying (95% confidence intervals). bLikelihood ratio statistic on one degree offreedom.
cReference category. dMean hazard ratio between two adjacent categories.
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between low bcl-2 expression and shortened overall survival
following univariate analysis in axillary node-positive but not
in axillary node-negative patients. Following multivariate
analysis no independent prognostic role for bcl-2 expression
was retained in axillary node-negative or in axillary node-
positive patients (Joensuu et al., 1994). In the present series
we studied the prognostic value of bcl-2 expression on
disease-free survival and overall survival in 231 breast cancer
patients initially staged as MO. Univariate analysis and mul-
tivariate analysis including established prognostic factors in
breast carcinoma demonstrated absence of bcl-2 expression to
be independently associated with shortened disease-free sur-
vival and shortened overall survival in axillary node-positive
breast cancer but not in axillary node-negative breast cancer.
The observed prognostic role for bcl-2 expression in the
complete study population mainly reflects its strong prognos-
tic value in axillary node-positive breast cancer. Our study
results in part confirm the results obtained in previous studies
but demonstrate an intriguing prognostic role for bcl-2 exp-
ression in axillary node-positive breast cancer.
In follicular lymphoma the presence of bcl-2 overexpres-
sion as a consequence of the t(14;18) translocation has no
prognostic value and appears to be a hallmark for slow
tumour progression (Pezzella et al., 1992). In non-small-cell
lung carcinoma the observation of a group of bcl-2-positive
tumours with relatively slow disease progression suggests a
role for bcl-2 expression as an initial oncogenic effect leading
to less aggressive tumour growth as observed in follicular
lymphoma (Pezzella et al., 1993). The observed difference in
independent prognostic power for bcl-2 expression between
axillary node-negative and axillary node-positive patients in
our series is extremely interesting and needs further elucida-
tion. In vitro and in vivo studies have demonstrated a role for
the bcl-2 protein in the prevention of apoptosis induced by
anti-cancer drugs (Campos et al., 1993; Miyashita and Reed,
1993). Bcl-2 transfection has been demonstrated to confer
resistance to anti-cancer agents by non-conventional drug-
resistance pathways (Fisher et al., 1993). A recent study in
breast cancer has reported bcl-2 immunostaining to be a
better predictor for response to systemic endocrine therapy
than oestrogen receptor status in a limited series of patients
who only received endocrine therapy following primary
surgery (Gee et al., 1994). In contrast to our findings, Joen-
suu et al. (1994) could not demonstrate a prognostic role for
bcl-2 expression on overall survival in axillary node-positive
breast cancer patients primarily treated by radical surgery
with or without locoregional radiotherapy and in whom no
adjuvant therapy was administered. These data and our
study results strongly suggest a role for bcl-2 expression as a
predictor for response to chemotherapy or endocrine therapy
in breast cancer patients. However, investigating such
interactions in our study population is problematic because
of the need for subgroup analysis in limited numbers of
patients and because of the heterogeneous character of
second-line and third-line treatment in those patients
developing locoregional disease relapse and/or distant metas-
tases which consists of various combinations of
chemotherapy and/or endocrine therapy and/or radiotherapy.
Larger patient groups with better standardised curative and
palliative treatment protocols are needed to study the role of
bcl-2 as a modulator of response to chemotherapy or endoc-
rine therapy in breast cancer.
To what extent bcl-2 expression influences apoptotic cell
death rate in solid neoplasms and its final effect on disease
progression remains to be resolved. Recently, cDNAs have
been cloned for several novel human genes, revealing a
family of bcl-2 related proteins. The bax protein has been
demonstrated to promote apoptosis by opposing bcl-2's func-
tion through heterodimerisation (Oltvai et al., 1993). Bcl-XL
has been shown to inhibit apoptosis, whereas its shorter
alternative splice form bcl-xs, promotes apoptosis (Boise et
al., 1993). The MCL1 gene and the Al gene have been
demonstrated to have sequence similarity with the bct-2 gene,
although their function remains unknown (Kozopas et al.,
1993; Lin et al., 1993). Other non-bcl-2-related proteins play-
ing a role in the regulation of programmed cell death have
been isolated (Gagliardini et al., 1993; Nakashima et al.,
1993).
Other important oncogenes and tumour-suppressor genes
play a role in the regulation of apoptosis. c-myc, although
generally considered as an important element in proliferation
control, induces apoptosis in specific conditions (Evan et al.,
1992; Shi et al., 1992). The action ofc-myc as a stimulator of
both mitogenesis and apoptosis appears to be dependent on
the presence of bcl-2 (Bissonnette et al., 1992; Fanidi et al.,
1992). Wild-type p53 has been demonstrated to be able to
induce apoptosis (Yonis-Rouach et al., 1991). The bcl-2 gene
is a transcriptional target for wild-type p53. Wild-type p53
decreases bcl-2 protein levels and increases bax protein levels
in vitro and in vivo, explaining the ability of p53 to induce
apoptotic cell death (Miyashita et al., 1994a,b). Furthermore,
in breast cancer cell lines mutant p53 induces down-
regulation of bcl-2 at both mRNA and protein level (Haldar
et al., 1994). The critical role played by p53 in the car-
cinogenesis of human breast cancer is well documented.
About 30-50% of human breast cancers carry a mutant p53
gene and about an additional 30% carry non-functional wild-
type p53 sequestered in the cytoplasm of tumour cells (Moll
et al., 1992). The presence of mutated or overexpressed p53
has been associated with poor prognostic markers, such as
high histopathological grading, high levels of Ki67 or EGFR
and the absence of hormone receptors, as well as with
shortened disease-free survival and/or overall survival (Cat-
toretti et al., 1988; Isola et al., 1992; Poller et al., 1992; Thor
et al., 1992; Allred et al., 1993). The inverse correlation
between bcl-2 expression and the presence of immunohis-
tochemically demonstrable mutant p53 observed in breast
cancer could reflect down-regulation of bcl-2 by mutant p53
(Doglioni et al., 1994; Joensuu et al., 1994; Leek et al., 1994;
Silvestrini et al., 1994).
We conclude absence of bcl-2 expression to be an indepen-
dent marker of poor prognosis in axillary node-positive
breast cancer. Absence of bcl-2 expression in invasive ductal
breast carcinoma possibly reflects down-regulation of the
bcl-2 gene by mutant p53. Our results suggest a potentially
important role for bcl-2 as a modulator of response to
adjuvant therapy in breast cancer.
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